PPTDF Stock Chart & Stats
$11.75
$0.00(0.00%)
At close: 4:00 PM EST
$11.75
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.45 - $13.24
Previous CloseN/A
Volume10.00
Average Volume (3M)53.00
Market Cap
$845.45M
Enterprise Value$120.76B
Total Cash (Recent Filing)$25.55B
Total Debt (Recent Filing)$16.34B
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.64
Shares Outstanding130,010,400
10 Day Avg. Volume0
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market Cap142.84
Enterprise Value/Revenue6.34
Enterprise Value/Gross Profit14.94
Enterprise Value/Ebitda-48.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.55
Revenue Forecast (FY)$269.07M
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery Platform (PDPS)PeptiDream’s PDPS is a durable competitive asset: proprietary discovery tech drives repeat collaborations, creates switching costs, and supports a pipeline of partner programs and PDCs. Over months this underpins recurring R&D revenue, licensing optionality and long-term IP value.
Material Top-line ReboundA +287% revenue surge indicates strong demand for discovery services and successful deal activity. Sustainably higher collaboration revenue increases potential for milestone and royalty streams, improving the company’s ability to scale operations and fund pipelines over the medium term.
Strengthened Senior Leadership TeamHiring experienced EVPs (operations, strategy, people) from Illumina, Astellas and Eisai materially upgrades commercial, operational and talent capabilities. Stronger leadership enhances execution, partner management and global scaling, which supports durable growth and program monetization.
Bears Say
Return To Losses And Margin ErosionReversion to negative margins undermines internal funding capacity for R&D and platform investment. If losses persist, management may need to cut programs or raise capital, increasing dilution risk and reducing long-term returns to shareholders and ability to sustain competitive R&D spend.
Negative Operating And Free Cash FlowA meaningful swing to negative OCF and FCF raises structural funding risk. Sustained cash burn can force external financing, constrain investment in PDPS and internal programs, and impair the company’s ability to capitalize on partnerships or support commercialization over the coming months.
High Reliance On Partner Deal Timing And MilestonesRevenue and cash are lumpy and dependent on discrete collaboration deals and milestone events. This structural volatility complicates planning and makes durable profitability and predictable cash generation dependent on partner development timelines, which can stretch over years.
Peptidream News
PPTDF FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was $5.45 and its highest was $13.24 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is $845.45M.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 40 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on May 13, 2026. The company reported -$0.041 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.009.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Overvalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -0.02.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -$0.041 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in PPTDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
PPTDF Company Deck
PPTDF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.View all PPTDF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
2.66% Mutual Funds
― Other Institutional Investors
93.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---